October 15, 2014 9:15 AM | 1 min read |
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published Wednesday, Bank of America analyst Juan C. Sanabria upgraded the rating on
Sabra Health Care REIT (NASDAQ: SBRA) from Neutral to Buy, and reiterated the $28.50 price target.In the report, Bank of America noted, “We are upgrading SBRA from Neutral to Buy on valuation with a $28.50 PO. We see SBRA as oversold trading at 11.3X 2015 AFFO (Exhibit 1), 28% below the HC sector weighted average. SBRA also screens attractive at a 7.2% implied cap rate, vs. AVIV (pure play SNF) at 7.3% & the HC sector at 6.3%. Our PO assumes SBRA trades at 13.5X forward four quarters AFFO, which is currently a 17% discount to diversified peers (HCN, HCP, NHI & VTR) and 9% discount to the sub-sector. At our PO, SBRA's implied cap rate would be 6.7% vs. diversified peers at 6.1%.”Sabra Health Care REIT closed on Tuesday at $24.92.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.